Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Return on Sales (2018 - 2025)

Cue Biopharma (CUE) has disclosed Return on Sales for 8 consecutive years, with 2.44% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 1254.0% to 2.44% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.31% through Dec 2025, up 43.0% year-over-year, with the annual reading at 0.19% for FY2025, 56.0% up from the prior year.
  • Return on Sales hit 2.44% in Q4 2025 for Cue Biopharma, up from 3.43% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 14.98% in Q4 2024 to a low of 508.0% in Q2 2022.
  • Historically, Return on Sales has averaged 45.83% across 5 years, with a median of 6.24% in 2021.
  • Biggest five-year swings in Return on Sales: tumbled -50425bps in 2022 and later soared 49863bps in 2023.
  • Year by year, Return on Sales stood at 0.96% in 2021, then crashed by -9763bps to 94.26% in 2022, then skyrocketed by 92bps to 7.1% in 2023, then skyrocketed by 311bps to 14.98% in 2024, then tumbled by -84bps to 2.44% in 2025.
  • Business Quant data shows Return on Sales for CUE at 2.44% in Q4 2025, 3.43% in Q3 2025, and 2.86% in Q2 2025.